The pharmacokinetics and pharmacodynamics of certain GLP-1RAs like liraglutide have been studied in both adult and pediatric populations [Reference Carlsson Petri, Hale, Hesse, Rathor and Mastrandrea21]
That is the question this guide answers, thoroughly and without spin
However, an increased rate of DKA led to rejection of market authorisation for type 1 diabetes by the FDA, whereas the European Medicines Agency has approved low-dose dapagliflozin (5 mg) and sotagliflozin (200 mg) for those with a BMI 27 kg/m 2 [261]
Kendler BS
[DOI] [PMC free article] [PubMed] [Google Scholar] 34.Molfino A, Cascino A, Conte C, Ramaccini C, Fanelli FR, Laviano A
Many see improvement by month 6 and more obvious volume recovery by month 912, assuming nutrition and health stabilize